GRCE

Grace Therapeutics Inc

1.86

Nov 10 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: MIST DMAC TENX HRTX CVKD CALC ICU UNCY ZVRA PCSA

| Held by: VTI IWC

Scroll to Statements

Index	-
Market Cap	39.13M
Enterprise Value	25.37M
Income	-20.22M
Sales	0.00M
Book/sh	2.96
Cash/sh	0.65
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	May 06, 2011

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.63
P/C	2.84
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.47
Current Ratio	11.47
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.18
EPS next Y	-0.47
EPS next Q	-0.15
EPS this Y	-43.62%
EPS next Y	31.11%
EPS next 5Y	-
EPS past 3/5Y	56.43% 43.17%
Sales past 3/5Y	- -
EPS Y/Y TTM	-43.60%
Sales Y/Y TTM	-
EPS Q/Q	-333.11%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-603.79% -

Insider Own	18.68%
Insider Trans	11.54%
Inst Own	32.99%
Inst Trans	-4.49%
ROA	-33.74%
ROE	-36.19%
ROIC	-41.94%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.56%
SMA50	-8.28%
SMA200	-32.42%
Trades

Shs Outstand	21.04M
Shs Float	17.11M
Short Float	9.75%
Short Ratio	13.01
Short Interest	1.67M
52W High	5.18 -64.09%
52W Low	1.67 11.38%
Volatility	6.70% 7.85%
ATR (14)	0.13
RSI (14)	44.53
Beta	0.41
Rel Volume	0.00
Avg Volume	128.13K
Volume	0

Perf Week	1.09%
Perf Month	-7.92%
Perf Quarter	-11.43%
Perf Half Y	-20.17%
Perf YTD	-46.24%
Perf Year	-37.79%
Perf 3Y	-16.36%
Perf 5Y	-81.44%
Perf 10Y	-97.01%
Recom	1.00
Target Price	6.00
Prev Close	1.86
Price	1.86
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$6.00

Implied Upside

+222.6%

Analysts4incl. previous ratings

Rating Distribution3 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 02, 2025	Initiated	TTD Cowen	Buy	$12	+545.2%
Sep 01, 2020	Downgrade	OOppenheimer	Outperform → Perform
Jul 06, 2020	Upgrade	BB. Riley FBR	Neutral → Buy	$2	+7.5%
Jan 13, 2020	Downgrade	BB. Riley FBR	Buy → Neutral
Aug 29, 2019	Initiated	BB. Riley FBR	Buy	$7.75	+316.7%
Jul 18, 2019	Initiated	OOppenheimer	Outperform	$7	+276.3%
Jun 26, 2019	Initiated	HH.C. Wainwright	Buy	$6	+222.6%

Nov-05-26 08:00AM	Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026 (GlobeNewswire)
Sep-03-26 08:00AM	Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-13-26 08:00AM	Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update (GlobeNewswire)
Aug-04-26 09:00PM	Grace Therapeutics Announces $10 Million Private Placement (GlobeNewswire)
Jul-28-26 07:00AM	Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration (GlobeNewswire)
08:00AM	Loading…
Jun-18-26 08:00AM	Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update (GlobeNewswire) +7.21%
Apr-23-26 01:13PM	Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104 (GlobeNewswire) -45.48%
Apr-14-26 08:00AM	Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 (GlobeNewswire) +12.04%
Mar-19-26 08:00AM	Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences (GlobeNewswire)
Feb-25-26 08:00AM	Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-12-26 08:00AM	Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update (GlobeNewswire)
Nov-17-25 08:00AM	Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference (GlobeNewswire)
Nov-13-25 08:00AM	Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update (GlobeNewswire)
Nov-11-25 08:30AM	Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting (GlobeNewswire)
Oct-23-25 08:00AM	Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review (GlobeNewswire)
08:00AM	Loading…
Sep-22-25 08:00AM	Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting (GlobeNewswire)
Sep-18-25 08:30AM	Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 (GlobeNewswire)
Sep-04-25 08:00AM	Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-27-25 08:00AM	Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 (GlobeNewswire)
Aug-12-25 08:00AM	Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update (GlobeNewswire)
Jun-25-25 08:00AM	Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104 (GlobeNewswire)
Jun-23-25 08:00AM	Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update (GlobeNewswire)
Jun-13-25 08:00AM	Grace Therapeutics to Participate in the 2025 BIO International Conference (GlobeNewswire)
Apr-09-25 08:00AM	Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104 (GlobeNewswire) +9.09%
Mar-11-25 07:00AM	Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Feb-25-25 08:00AM	Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -7.19%
Feb-13-25 08:00AM	Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update (GlobeNewswire)
Feb-11-25 10:26AM	Grace Therapeutics secures $15m for GTx-104 pre-commercial development (Pharmaceutical Technology)
Feb-10-25 12:05PM	Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study (Benzinga) +8.33%
08:05AM	Grace Therapeutics Announces Private Placement Financing of up to $30 Million (GlobeNewswire)
08:01AM	Loading…
08:01AM	Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH (GlobeNewswire)
Jan-07-25 08:00AM	Grace Therapeutics to Participate in Upcoming Investor Events January 2025 (GlobeNewswire)
Dec-04-24 08:00AM	Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference (GlobeNewswire) +20.00%
Nov-13-24 08:00AM	Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update (GlobeNewswire)
Oct-30-24 08:00AM	Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024 (GlobeNewswire)
Oct-25-24 08:00AM	Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. (GlobeNewswire)
Sep-25-24 07:30AM	Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 (GlobeNewswire) +19.53%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) +12.43%
Sep-12-24 08:00AM	Acasti to Present at the Life Sciences Investor Forum (GlobeNewswire) -8.38%
Sep-05-24 10:35AM	Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-09-24 02:52PM	ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025 (InvestorPlace)
08:00AM	Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update (GlobeNewswire)
Jul-10-24 09:40AM	Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-27-24 04:05PM	Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial (GlobeNewswire)
Jun-21-24 01:53PM	ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024 (InvestorPlace)
08:00AM	Acasti Announces Year-End 2024 Financial Results, Provides Business Update (GlobeNewswire)
Jun-18-24 12:31PM	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
May-28-24 04:05PM	Acasti Pharma to Attend BIO International Convention 2024 (GlobeNewswire)
May-23-24 06:45AM	The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom (InvestorPlace)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Feb-12-24 08:00AM	Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +6.53%
07:57AM	Acasti: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Feb-01-24 08:00AM	Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial (GlobeNewswire)
Dec-13-23 08:00AM	Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024 (GlobeNewswire)
Nov-13-23 08:20AM	Acasti: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Acasti Announces Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Oct-23-23 08:00AM	Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial (GlobeNewswire)
Oct-04-23 08:00AM	Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH) (GlobeNewswire)
Sep-26-23 08:00AM	Acasti Announces $7.5 Million Private Placement Equity Financing (GlobeNewswire) +35.39%
Sep-06-23 08:00AM	Acasti to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-23-23 03:49AM	TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised) (Zacks)
Aug-22-23 09:19AM	TEVA to Pay $250 Million to Settle Price-Fixing Charges (Zacks)
Aug-11-23 07:10AM	Acasti: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Acasti Announces First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Aug-09-23 04:05PM	Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting (GlobeNewswire)
Jul-28-23 08:02AM	Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates (Zacks)
Jul-10-23 09:00AM	Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients (PR Newswire) -9.55%
Jul-07-23 08:00AM	Acasti Pharma Announces 1-for-6 Reverse Stock Split (PR Newswire) -12.52%
Jul-05-23 09:00AM	Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 (PR Newswire) +18.77%
Jun-23-23 07:00AM	Acasti Pharma Reports Fiscal Year 2023 Operational Results (PR Newswire)
Jun-22-23 09:00AM	Acasti Announces Appointment of New Scientific Advisory Board Members (PR Newswire)
May-17-23 09:00AM	Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference (PR Newswire)
May-10-23 07:41AM	We're Hopeful That Acasti Pharma (NASDAQ:ACST) Will Use Its Cash Wisely (Simply Wall St.)
May-08-23 07:00AM	Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025 (PR Newswire)
Apr-04-23 08:01AM	Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND (PR Newswire)
08:00AM	Acasti Announces Appointment of Prashant Kohli as CEO (PR Newswire)
Mar-30-23 08:30AM	Acasti Pharma Inc. Announces the Resignation of a Director (PR Newswire)
06:57AM	When Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit? (Simply Wall St.)
Mar-13-23 08:00AM	Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange (PR Newswire)
Mar-08-23 09:00AM	Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Mar-04-23 08:28AM	We're Hopeful That Acasti Pharma (CVE:ACST) Will Use Its Cash Wisely (Simply Wall St.)
Feb-28-23 01:00PM	Acasti Pharma Recognizes Rare Disease Day (PR Newswire)
09:40AM	Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-15-23 04:02PM	Acasti Pharma Inc. (NASDAQ:ACST) Q3 2023 Earnings Call Transcript (Insider Monkey)
Feb-14-23 07:00AM	Acasti Pharma Reports Third Quarter 2023 Operational Results (GlobeNewswire)
Feb-07-23 09:00AM	Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023 (PR Newswire)
Jan-25-23 09:00AM	Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule (GlobeNewswire)
Jan-24-23 04:15PM	Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31 (GlobeNewswire)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE) +5.63%
08:45AM	Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast (Newsfile)
Jan-13-23 09:00AM	Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18 (GlobeNewswire)
Jan-05-23 09:00AM	Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures (GlobeNewswire) +18.32%
Dec-29-22 06:02AM	Acasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call Transcript (Insider Monkey)
Dec-28-22 08:00AM	Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Companys Drug Candidate for the Treatment of Ataxia Telangiectasia (GlobeNewswire) +11.09%
Dec-22-22 08:00AM	Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Companys Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN) (GlobeNewswire) +11.99%
Nov-14-22 07:00AM	Acasti Pharma Reports Second Quarter 2023 Operational Results (GlobeNewswire)
Nov-09-22 04:15PM	Acasti Pharma to Present at Q4 Investor Summit (GlobeNewswire)
Nov-07-22 04:15PM	Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022 (GlobeNewswire) -6.01%
Sep-30-22 09:00AM	Acasti Announces Court Dismissal of Stockholder Litigation (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Nov 03 '26	Buy	1.79	10,328	18,481	3,046,739	Nov 05 09:05 PM
Opaleye Management Inc.	10% Owner	Nov 04 '26	Buy	1.80	5,027	9,060	3,051,766	Nov 05 09:05 PM
Opaleye Management Inc.	10% Owner	Nov 05 '26	Buy	1.77	3,087	5,478	3,054,853	Nov 05 09:05 PM
Opaleye Management Inc.	10% Owner	Oct 26 '26	Buy	1.77	66,411	117,408	3,036,411	Oct 26 06:06 PM
Opaleye Management Inc.	10% Owner	Oct 22 '26	Buy	1.93	21,390	41,193	2,970,000	Oct 26 06:06 PM
Opaleye Management Inc.	10% Owner	Oct 19 '26	Buy	1.88	4,256	8,001	2,948,610	Oct 21 06:06 PM
Opaleye Management Inc.	10% Owner	Oct 16 '26	Buy	1.89	36,347	68,758	2,944,354	Oct 16 08:42 PM
Opaleye Management Inc.	10% Owner	Oct 15 '26	Buy	1.95	23,485	45,685	2,908,007	Oct 16 08:42 PM
Opaleye Management Inc.	10% Owner	Oct 14 '26	Buy	1.93	11,233	21,735	2,884,522	Oct 16 08:42 PM
Opaleye Management Inc.	10% Owner	Oct 12 '26	Buy	2.02	7,215	14,574	2,873,289	Oct 13 05:45 PM
Opaleye Management Inc.	10% Owner	Oct 09 '26	Buy	2.04	5,340	10,918	2,866,074	Oct 13 05:45 PM
Opaleye Management Inc.	10% Owner	Oct 08 '26	Buy	2.02	2,077	4,190	2,860,734	Oct 13 05:45 PM
Opaleye Management Inc.	10% Owner	Oct 01 '26	Buy	2.04	38,796	78,961	2,836,963	Oct 05 06:46 PM
Opaleye Management Inc.	10% Owner	Oct 02 '26	Buy	2.07	20,000	41,368	2,856,963	Oct 05 06:46 PM
Opaleye Management Inc.	10% Owner	Oct 05 '26	Buy	2.06	1,694	3,490	2,858,657	Oct 05 06:46 PM
Opaleye Management Inc.	10% Owner	Sep 29 '26	Buy	2.09	7,849	16,404	2,798,167	Oct 01 04:30 PM
Opaleye Management Inc.	10% Owner	Sep 21 '26	Buy	2.10	9,771	20,519	2,850,000	Sep 23 06:19 PM
Opaleye Management Inc.	10% Owner	Sep 23 '26	Buy	2.10	5,318	11,168	2,855,318	Sep 23 06:19 PM
Opaleye Management Inc.	10% Owner	Sep 08 '26	Buy	2.10	9,393	19,699	2,769,393	Sep 10 04:05 PM
Opaleye Management Inc.	10% Owner	Sep 09 '26	Buy	2.09	5,836	12,197	2,775,229	Sep 10 04:05 PM
Kohli Prashant	Chief Executive Officer	Sep 09 '26	Buy	2.14	100,000	214,000	121,357	Sep 10 07:30 AM
Opaleye Management Inc.	10% Owner	Aug 14 '26	Buy	2.09	11,608	24,206	2,760,000	Aug 19 07:44 AM

Grace Therapeutics, Inc. engages in the development and commercialization of drug candidates for rare and orphan diseases. It focuses on utilizing proprietary technologies to improve the performance of currently marketed drugs. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

CEO & DirectorMr. Prashant Kohli

VP of Program ManagementMr. Amresh Kumar Ph.D.

ConsultantMs. Carrie D'Andrea

VP of Finance and Principal Financial & Accounting OfficerMr. Robert J. DelAversano CPA

Ph.D.Dr. R. Loch MacDonald M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

GRCE

Grace Therapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.